Form 4: Astronics Corp. VP Mark Peabody Reports Stock Transactions
SEC Form 4
Mark Peabody, VP of Astronics Advanced Electronic Systems, reports acquisition of shares via bonus and 401(k) contributions, as well as shares withheld for tax obligations.
Summary
- Mark Peabody, VP at Astronics Corp., filed a Form 4 detailing changes in beneficial ownership.
- On May 10, 2024, Peabody acquired 338 shares of common stock as a bonus for Q1 2024, paid in shares instead of cash.
- Also on May 10, 2024, 83 shares were withheld to cover withholding taxes related to the bonus.
- On May 13, 2024, Peabody acquired 194.915 shares through the issuer's 401(k) plan at a price of $18.89 per share.
- Peabody directly owns 44,887.851 shares of common stock after these transactions.
- Peabody also holds options and restricted stock units (RSUs) that convert into common stock.
- Vesting of certain RSUs depends on Astronics Corp.'s average annual adjusted EBITDA over specific periods.
Sentiment
Score: 6
Explanation: The document is a routine filing, but the acquisition of shares by a VP and the performance-based vesting of RSUs are mildly positive signals.
Positives
- The acquisition of shares through the bonus plan and 401(k) contribution indicates Peabody's continued investment in Astronics Corp.
- The bonus being paid in shares aligns Peabody's interests with those of the shareholders.
Negatives
- The withholding of shares for taxes reduces the immediate gain from the stock bonus.
Risks
- The vesting of a significant portion of Peabody's restricted stock units is contingent on Astronics Corp.'s future financial performance, specifically its average annual adjusted EBITDA.
- Failure to meet the EBITDA targets could result in a lower vesting percentage for these RSUs.
Future Outlook
The vesting of restricted stock units is dependent on the company's future EBITDA performance, indicating a focus on achieving specific financial targets.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's prospects. The aerospace industry is currently experiencing a recovery, which may be reflected in the company's EBITDA performance.
Comparison to Industry Standards
- Comparing Astronics' executive compensation structure, particularly the use of EBITDA-linked RSUs, to companies like HEICO Corporation (HEI) or TransDigm Group (TDG) would provide context on whether their performance-based incentives are aligned with industry norms.
- For example, HEICO often uses stock options and performance-based bonuses tied to revenue and profit growth, while TransDigm relies heavily on equity-based compensation to align management interests with shareholders.
- Analyzing the vesting schedules and performance metrics of these companies' equity grants can help determine if Astronics' approach is more or less aggressive in incentivizing executive performance.
Stakeholder Impact
- Shareholders may view the stock bonus and 401(k) contributions as a sign of management's commitment.
- Employees participating in the 401(k) plan benefit from the company's contributions.
Key Dates
| Date | Description |
|---|---|
| 12/11/2015 | Date of option grant with exercise price of $30.83 and expiration on 12/11/2024 |
| 12/03/2016 | Date of option grant with exercise price of $27.72 and expiration on 12/03/2025 |
| 12/14/2017 | Date of option grant with exercise price of $31.76 and expiration on 12/14/2026 |
| 12/12/2018 | Date of option grant with exercise price of $35.61 and expiration on 12/12/2027 |
| 12/13/2019 | Date of option grant with exercise price of $31.57 and expiration on 12/13/2028 |
| 12/09/2020 | Date of option grant with exercise price of $30.04 and expiration on 12/09/2029 |
| 01/01/2021 | Start date for EBITDA performance period for certain RSUs |
| 12/09/2022 | Date of option grant with exercise price of $11.13 and expiration on 12/09/2031 |
| 01/22/2022 | Date of option grant with exercise price of $14.45 and expiration on 01/22/2031 |
| 01/01/2022 | Start date for EBITDA performance period for certain RSUs |
| 01/01/2023 | Start date for EBITDA performance period for certain RSUs |
| 12/16/2023 | Date of option grant with exercise price of $9.74 and expiration on 12/16/2032 |
| 12/31/2023 | End date for EBITDA performance period for certain RSUs |
| 01/01/2024 | Start date for EBITDA performance period for certain RSUs |
| 05/10/2024 | Date of stock bonus award and shares withheld for taxes |
| 05/13/2024 | Date of 401(k) share acquisition |
| 12/07/2024 | Date of option grant with exercise price of $15.15 and expiration on 12/07/2033 |
| 12/11/2024 | Expiration date for options granted on 12/11/2015 |
| 12/03/2025 | Expiration date for options granted on 12/03/2016 |
| 02/23/2026 | Potential vesting date for RSUs based on 2023-2025 EBITDA performance |
| 12/14/2026 | Expiration date for options granted on 12/14/2017 |
| 12/12/2027 | Expiration date for options granted on 12/12/2018 |
| 02/22/2027 | Potential vesting date for RSUs based on 2024-2026 EBITDA performance |
| 12/13/2028 | Expiration date for options granted on 12/13/2019 |
| 12/09/2029 | Expiration date for options granted on 12/09/2020 |
| 12/09/2031 | Expiration date for options granted on 12/09/2022 |
| 01/22/2031 | Expiration date for options granted on 01/22/2022 |
| 12/16/2032 | Expiration date for options granted on 12/16/2023 |
| 12/07/2033 | Expiration date for options granted on 12/07/2024 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.